Improving CAR T cell therapy for better cancer treatment
Official title: Enhancing CAR T cell fitness using novel epigenetic reprogramming factors
Funded at Children's Hosp of Philadelphia · NIH-10910386 · Data updated 2026-11-12
This study is looking at ways to make CAR T cell therapy work better for people with certain blood cancers by improving the strength and effectiveness of the T cells, which could help them fight cancer more successfully.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hosp of Philadelphia NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $1,602,000 |
| NIH project number | 1DP2CA301078-01 |
| Project ID | NIH-10910386 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with B cell malignancies who have not responded well to existing CAR T cell therapies.
✕Less likely to help
Patients with solid tumors that are not B cell malignancies may not benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness of CAR T cell therapy, which is a treatment for certain types of blood cancers. The study aims to address the issue of poor T cell fitness, which limits the ability of these engineered cells to persist and fight tumors effectively. By developing novel epigenetic reprogramming factors, the researchers hope to improve the functionality of CAR T cells, making them more capable of targeting and eliminating cancer cells. Patients may benefit from this innovative approach if it leads to more durable responses and better outcomes in cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to more effective CAR T cell therapies that provide longer-lasting remissions for patients with B cell malignancies.
How similar studies have gone: While CAR T cell therapy has shown promise, the specific approach of using novel epigenetic reprogramming factors is relatively new and has not been extensively tested in prior studies.
Where this research is happening
-
Children's Hosp of Philadelphia
Philadelphia, United States Active
Researchers
- Principal investigator: Weber, Evan William — Children's Hosp of Philadelphia
- Study coordinator: Weber, Evan William
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.